iShares MSCI South Korea ETF vs Tempus AI — how do they compare? iShares MSCI South Korea ETF trades at $176.97 (market cap $26.25B), while Tempus AI trades at $70.06 (market cap $12.58B). The key difference: iShares MSCI South Korea ETF is far larger — about 2.1× Tempus AI's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Tempus AI for 22 Days on average.
| EWY | TEM | |
|---|---|---|
Market Cap | $26.25B | $12.58B |
Volume | 19,056,075 | 7,444,569 |
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $219.20 | $99.28 |
52-Week Low | $80.72 | $41.55 |
Typical Hold Time | 46 Days | 22 Days |
Enterprise Value | — | $13.21B |
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) is trading at $176.77, down 3.78% amid broader Asian market pressures. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term support. Recent volatility reflects sensitivity to semiconductor cycles, with heavy concentration in Samsung and SK hynix driving performance. South Korea's KOSPI has struggled to maintain gains above 7,000 despite AI-driven optimism, facing headwinds from rising oil prices and global bond yields.
The outlook remains tied to semiconductor demand and AI infrastructure spending, with corporate earnings showing resilience. Key risks include concentration in two holdings, memory cycle dependency, and macroeconomic pressures. Governance reforms and visible deleveraging provide fundamental support, but the ETF's high sensitivity to tech sector volatility warrants caution for risk-averse investors.
Tempus AI (TEM) trades at $72.15, up 2.65% today, with a bullish technical signal and strong analyst support. The stock shows recent earnings beats but remains unprofitable, with a net income margin of -17.77% for 2026. Positive developments include FDA clearance for an AI product and expanded data partnerships, fueling investor optimism in the healthtech sector.
Outlook is cautiously optimistic given growth potential in AI-driven diagnostics, but high valuation (P/S 8.61) and persistent losses pose risks. Upside hinges on revenue scaling and path to profitability, with a consensus price target of $72.60 suggesting limited near-term gains from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →